NEW YORK – Investment bank Oppenheimer on Wednesday initiated coverage on diagnostics company Bionano Genomics with a rating of Outperform and a price target of $1.50.
In a note to investors, analyst Kevin DeGeeter said the company is transitioning from selling optical mapping equipment to research labs to selling clinical diagnostics that have the potential to replace microarrays for cytogenetics analysis.